X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pdgfb (48) 48
humans (41) 41
index medicus (32) 32
platelet-derived growth factor (26) 26
female (23) 23
male (22) 22
dermatofibrosarcoma protuberans (19) 19
proto-oncogene proteins c-sis - genetics (18) 18
middle aged (16) 16
adult (14) 14
basal ganglia calcification (13) 13
animals (12) 12
calcification (12) 12
dermatofibrosarcoma - genetics (12) 12
slc20a2 (12) 12
dermatofibrosarcoma - pathology (11) 11
dermatology (11) 11
oncology (11) 11
skin neoplasms - genetics (11) 11
aged (10) 10
expression (10) 10
gene (10) 10
genetic aspects (10) 10
genetics & heredity (10) 10
skin neoplasms - pathology (10) 10
mutation (9) 9
neurosciences (9) 9
proto-oncogene proteins c-sis - metabolism (9) 9
sarcoma (9) 9
cancer (8) 8
clinical neurology (8) 8
col1a1 (8) 8
collagen type i - genetics (8) 8
mice (8) 8
mutations (8) 8
pathology (8) 8
primary familial brain calcification (8) 8
tumors (8) 8
analysis (7) 7
cell biology (7) 7
genes (7) 7
growth factors (7) 7
growth-factor (7) 7
imatinib mesylate (7) 7
neurology (7) 7
oncogene proteins, fusion - genetics (7) 7
pdgfrb (7) 7
pericytes (7) 7
receptor, platelet-derived growth factor beta - genetics (7) 7
transformation (7) 7
translocation, genetic (7) 7
adolescent (6) 6
angiogenesis (6) 6
basal ganglia (6) 6
base sequence (6) 6
giant-cell fibroblastoma (6) 6
reverse transcriptase polymerase chain reaction (6) 6
b-chain gene (5) 5
biochemistry & molecular biology (5) 5
brain calcification (5) 5
brain diseases - genetics (5) 5
calcinosis - genetics (5) 5
calcinosis - pathology (5) 5
developmental biology (5) 5
exons (5) 5
genetic research (5) 5
immunohistochemistry (5) 5
pdgf-b (5) 5
psychiatry (5) 5
research (5) 5
sodium-phosphate cotransporter proteins, type iii - genetics (5) 5
spectrum (5) 5
vegf (5) 5
aged, 80 and over (4) 4
antineoplastic agents - therapeutic use (4) 4
areas (4) 4
blood-brain barrier (4) 4
col1a1-pdgfb fusion transcripts (4) 4
fahr disease (4) 4
fibrosarcoma (4) 4
fluorescence (4) 4
gene rearrangement (4) 4
hematology, oncology and palliative medicine (4) 4
identification (4) 4
in situ hybridization, fluorescence (4) 4
medicine & public health (4) 4
molecular sequence data (4) 4
nervous system diseases (4) 4
phosphates (4) 4
polymerase chain-reaction (4) 4
receptor, platelet-derived growth factor beta - metabolism (4) 4
sequence analysis, dna (4) 4
survival (4) 4
young adult (4) 4
animal models (3) 3
benzamides (3) 3
bfgf (3) 3
biomedicine (3) 3
brain diseases - pathology (3) 3
breast cancer (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 2015, Volume 16, Issue 14, pp. 5647 - 5654
Journal Article
Pharmacology and Therapeutics, ISSN 0163-7258, 03/2017, Volume 171, pp. 30 - 42
Pericytes are a heterogeneous population of cells located in the blood vessel wall. They were first identified in the 19th century by Rouget, however their... 
Pericytes | Perivascular stem cells | Diabetic retinopathy | Diabetic nephropathy | Pericyte fibrosis | Cancer stem cells | DIABETIC-RETINOPATHY | Cancer stern cells | VEGF-A | BLOOD-BRAIN-BARRIER | MESENCHYMAL STEM-CELLS | EPITHELIUM-DERIVED FACTOR | HIGH GLUCOSE | PHARMACOLOGY & PHARMACY | STROMAL CELLS | TUMOR-GROWTH | GLYCATION END-PRODUCTS | ENDOTHELIAL GROWTH-FACTOR | Neoplasms - therapy | Animals | Diabetes Mellitus - physiopathology | Vascular Diseases - therapy | Diabetes Mellitus - therapy | Humans | Pericytes - cytology | Ischemia - therapy | Vascular Diseases - physiopathology | Ischemia - physiopathology | Molecular Targeted Therapy | Neoplasms - pathology | Blood circulation disorders | Therapeutics | Homeopathy | Materia medica and therapeutics | Impotence | Diabetic nephropathies | T cells | Muscle proteins | Cardiovascular agents | Blood coagulation factor VIII | Interleukins | Chronic kidney failure | Type 1 diabetes | Stem cells | Vascular endothelial growth factor | Mitogens | Protein kinases | Growth factors | UUO, unilateral ureteric obstruction | EGFR, EGF receptor | EMT, epithelial-mesenchymal transition | SFT, solitary fibrous tumour | DAN, diabetic autonomous neuropathy | ECM, extracellular matrix | NRF2, nuclear factor (erythroid-derived 2)-like 2 | IL-6, interleukin 6 | PSC, perivascular stem cell | BBB, blood-brain barrier | SOD, super oxide dismutase | HIF, hypoxia inducible factor | ED, erectile dysfunction | SDF-1, stromal derived factor 1 | RAGE, receptors of AGEs | CKD, chronic kidney disease | MMP, matrix metalloproteinases | MDSC, myeloid-derived suppressor cells | DN, diabetic nephropathy | TGF β, transforming growth factor β | PDL-1, programmed death-ligand 1 | ANG2, angiopoietin-2 | Olmfl3, Olfactomedin-like 3 | VEGF, vascular endothelial growth factor | AGE, Advanced Glycation End-Products | EC, endothelial cells | NG2, neural | R, ischemia-reperfusion | MSC, mesenchymal stromal cell | MF-EGF8, milk fat globule epidermal growth factor VIII | IL-8, interleukin 8 | glial antigen 2 | T1D, type 1 diabetic | PDGFb, platelet-derived growth factor B | MAPK, mitogen-activated protein kinase | PDGFRβ, platelet derived growth factor receptor β | DR, diabetic retinopathy | CNS, blood-retinal barrier | HB-EGF, heparin-binding EGF-like growth factor | HPC, hemangiopericytoma | PDR, proliferative diabetic retinopathy | DME, diabetic macular oedema | GFR, glomerular filtration rate | MI, myocardial infarction | SMA, smooth muscle actin | CSC, cancer stem cell | NPDR, non-proliferative diabetic retinopathy | T2D, type 2 diabetic | ROS, reactive oxygen species | Treg, regulatory T cells | BRB, blood-retina barrier | PKC, protein kinase C | DPN, diabetic peripheral neuropathy | TME, tumour microenvironment | ANG1, angiopoietin-1 | GSC, glioblastoma CSC | iPS, induced pluripotent stem cells | GSI, g-secretase inhibitor | FGF-9, fibroblastic growth factor 9 | PEDF, Pigment Epithelium-Derived Factor
Journal Article
Aging, ISSN 1945-4589, 2013, Volume 5, Issue 7, pp. 531 - 538
.... Here we show that normal human dermal fibroblasts display a complex response to Platelet derived growth factor B (PDGFB) expression... 
PDGFB | Senescence | Transformation | Sarcoma | CELLS | sarcoma | FUSION | IN-SITU HYBRIDIZATION | DERMATOFIBROSARCOMA PROTUBERANS | transformation | ONCOGENE-INDUCED SENESCENCE | CANCER | P53 | CELL BIOLOGY | senescence | ELEMENTS
Journal Article
Autophagy, ISSN 1554-8627, 12/2014, Volume 10, Issue 12, pp. 2171 - 2192
SNCA/α-synuclein aggregation plays a crucial role in synucleinopathies such as Parkinson disease and dementia with Lewy bodies. Aggregating and nonaggregating... 
GFAP, glial fibrillary acidic protein | HSPA8/Hsc70, heat shock 70kDa protein 8 | lysosomal degradation | BafA1, bafilomycinA | CASP3/aCasp3, caspase-3 | ESCRT, endosomal sorting complex required for transport | PF, particle fraction | ANXA5, annexin A5 | SNCA-T, tagged α-synuclein | PDGFB/PDGFb, platelet-derived growth factor subunit b | PD, Parkinson disease | S100B/S100b, S100 calcium-binding protein B | HRP, horseradish peroxidase | TUBB3/b-III-Tub, tubulin, β 3 class III | AIF1/Iba1, allograft inflammatory factor 1 | α-synuclein | CA1, cornu ammonis field1 | RT, room temperature | ILVs, intraluminal vesicles | LAMP2A/Lamp2a, lysosomal-associated membrane protein 2, isoform A | MAP2, microtubule-associated protein 2 | SYP, synaptophysin | CD63, CD63 molecule | LN, Lewy neuritis | ALP, autophagy-lysosomal pathway | RAB11A/rab11, member RAS oncogene family | secretion | EV, empty vector | protein aggregation | TNF/TNFa, tumor necrosis factor α | WT-SNCA, wild-type α-synuclein | CSF, cerebrospinal fluid | RBFOX3/NeuN, RNA binding protein, fox-1 homolog (C. elegans) 3 | DLB, dementia with Lewy bodies | CM, conditioned medium | tg, transgenic | Parkinson disease | ML, molecular layer | ACTB/bAct, actin, β | ER, endoplasmatic reticulum | synucleinopathies | SL, stratum lacunosum; SNCA/aSyn | SNCAIP/Sph1, synphilin-1 | CMA, chaperone-mediated autophagy | inflammation | Neoctx, neocortex | UPS, ubiquitin proteasome system | IL6/IL-6, interleukin-6 | N, neuron | LB, Lewy bodies | MVBs, multivesicular bodies | PS, phosphatidylserine | Hippo, hippocampus | AK, adenylate kinase | Protein aggregation | Lysosomal degradation | Secretion | Synucleinopathies | Inflammation | CALCIUM-DEPENDENT MANNER | CHAPERONE-MEDIATED AUTOPHAGY | LEWY BODY DISEASE | alpha-synuclein | CELL-DEATH | CELL BIOLOGY | TRANSMISSION | MULTIVESICULAR BODIES | PROTEIN-DEGRADATION | NEURONS | PARKINSONS-DISEASE | Animals | Rats, Wistar | Humans | Cells, Cultured | Mice, Transgenic | Signal Transduction - physiology | Autophagy - physiology | Mice | Neurons - metabolism | Parkinson Disease - metabolism | Lewy Bodies - metabolism | alpha-Synuclein - metabolism
Journal Article
Journal Article
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2011, Volume 76, Issue 3, pp. 393 - 396
.... Baseline serum levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), thrombospondin-1 (TSP-1... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | PDGFB | VEGF Receptor | Molecular targeted therapy | Mesothelioma | Clinical trial phase II | Vatalanib | SURVIVAL | CELLS | ANGIOGENESIS | VEGF | BETA | ONCOLOGY | RESPIRATORY SYSTEM | FACTOR PDGF | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Male | Mesothelioma - mortality | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Pyridines - therapeutic use | Phthalazines - administration & dosage | Pyridines - administration & dosage | Vascular Endothelial Growth Factor A - blood | Treatment Outcome | Mesothelioma - drug therapy | Biomarkers, Tumor - blood | Protein Kinase Inhibitors - administration & dosage | Phthalazines - therapeutic use | Mesothelioma - blood | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | GPI-Linked Proteins - blood | Platelet-Derived Growth Factor | Aged | Phthalazines - adverse effects | Thrombospondin 1 - blood | Platelet-derived growth factor | Endothelial growth factors | Leukemia | Clinical trials | Angiogenesis inhibitors | Vascular endothelial growth factor | Index Medicus | molecular targeted therapy | clinical trial phase II | vatalanib
Journal Article
Journal Article
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 08/2018, Volume 233, Issue 8, pp. 5949 - 5961
Journal Article